PMC:7361216 / 7064-8033 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T84","span":{"begin":54,"end":61},"obj":"Body_part"},{"id":"T85","span":{"begin":134,"end":141},"obj":"Body_part"},{"id":"T86","span":{"begin":318,"end":331},"obj":"Body_part"},{"id":"T87","span":{"begin":367,"end":374},"obj":"Body_part"},{"id":"T88","span":{"begin":477,"end":489},"obj":"Body_part"},{"id":"T89","span":{"begin":633,"end":645},"obj":"Body_part"},{"id":"T90","span":{"begin":784,"end":799},"obj":"Body_part"},{"id":"T91","span":{"begin":877,"end":891},"obj":"Body_part"},{"id":"T92","span":{"begin":932,"end":944},"obj":"Body_part"}],"attributes":[{"id":"A84","pred":"fma_id","subj":"T84","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A85","pred":"fma_id","subj":"T85","obj":"http://purl.org/sig/ont/fma/fma82801"},{"id":"A86","pred":"fma_id","subj":"T86","obj":"http://purl.org/sig/ont/fma/fma82737"},{"id":"A87","pred":"fma_id","subj":"T87","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A88","pred":"fma_id","subj":"T88","obj":"http://purl.org/sig/ont/fma/fma82737"},{"id":"A89","pred":"fma_id","subj":"T89","obj":"http://purl.org/sig/ont/fma/fma82737"},{"id":"A90","pred":"fma_id","subj":"T90","obj":"http://purl.org/sig/ont/fma/fma82746"},{"id":"A91","pred":"fma_id","subj":"T91","obj":"http://purl.org/sig/ont/fma/fma82746"},{"id":"A92","pred":"fma_id","subj":"T92","obj":"http://purl.org/sig/ont/fma/fma82737"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T18","span":{"begin":548,"end":556},"obj":"Disease"}],"attributes":[{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T92","span":{"begin":72,"end":74},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T93","span":{"begin":280,"end":281},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T94","span":{"begin":336,"end":337},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T95","span":{"begin":386,"end":387},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T96","span":{"begin":414,"end":415},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T97","span":{"begin":467,"end":468},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T98","span":{"begin":666,"end":667},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T99","span":{"begin":895,"end":896},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T52","span":{"begin":54,"end":61},"obj":"Chemical"},{"id":"T53","span":{"begin":134,"end":141},"obj":"Chemical"},{"id":"T54","span":{"begin":167,"end":174},"obj":"Chemical"},{"id":"T55","span":{"begin":318,"end":331},"obj":"Chemical"},{"id":"T56","span":{"begin":367,"end":374},"obj":"Chemical"},{"id":"T57","span":{"begin":388,"end":395},"obj":"Chemical"},{"id":"T58","span":{"begin":396,"end":404},"obj":"Chemical"},{"id":"T59","span":{"begin":477,"end":489},"obj":"Chemical"},{"id":"T60","span":{"begin":574,"end":585},"obj":"Chemical"},{"id":"T61","span":{"begin":633,"end":645},"obj":"Chemical"},{"id":"T62","span":{"begin":668,"end":675},"obj":"Chemical"},{"id":"T63","span":{"begin":784,"end":799},"obj":"Chemical"},{"id":"T64","span":{"begin":877,"end":891},"obj":"Chemical"},{"id":"T65","span":{"begin":906,"end":913},"obj":"Chemical"},{"id":"T66","span":{"begin":932,"end":944},"obj":"Chemical"}],"attributes":[{"id":"A52","pred":"chebi_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A53","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_37684"},{"id":"A54","pred":"chebi_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/CHEBI_18154"},{"id":"A55","pred":"chebi_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/CHEBI_16646"},{"id":"A56","pred":"chebi_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A57","pred":"chebi_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/CHEBI_78059"},{"id":"A58","pred":"chebi_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"},{"id":"A59","pred":"chebi_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/CHEBI_16646"},{"id":"A60","pred":"chebi_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A61","pred":"chebi_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/CHEBI_16646"},{"id":"A62","pred":"chebi_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/CHEBI_78059"},{"id":"A63","pred":"chebi_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/CHEBI_18154"},{"id":"A64","pred":"chebi_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/CHEBI_18154"},{"id":"A65","pred":"chebi_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/CHEBI_78059"},{"id":"A66","pred":"chebi_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/CHEBI_16646"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T28","span":{"begin":90,"end":95},"obj":"http://purl.obolibrary.org/obo/BFO_0000029"},{"id":"T29","span":{"begin":202,"end":207},"obj":"http://purl.obolibrary.org/obo/BFO_0000029"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T47","span":{"begin":54,"end":61},"obj":"Chemical"},{"id":"T48","span":{"begin":134,"end":141},"obj":"Chemical"},{"id":"T49","span":{"begin":167,"end":174},"obj":"Chemical"},{"id":"T50","span":{"begin":318,"end":331},"obj":"Chemical"},{"id":"T51","span":{"begin":367,"end":374},"obj":"Chemical"},{"id":"T52","span":{"begin":439,"end":444},"obj":"Chemical"},{"id":"T53","span":{"begin":477,"end":489},"obj":"Chemical"},{"id":"T54","span":{"begin":574,"end":585},"obj":"Chemical"},{"id":"T55","span":{"begin":633,"end":645},"obj":"Chemical"},{"id":"T56","span":{"begin":784,"end":799},"obj":"Chemical"},{"id":"T57","span":{"begin":877,"end":891},"obj":"Chemical"},{"id":"T58","span":{"begin":932,"end":944},"obj":"Chemical"}],"attributes":[{"id":"A49","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_18154"},{"id":"A57","pred":"chebi_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/CHEBI_18154"},{"id":"A53","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_16646"},{"id":"A48","pred":"chebi_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/CHEBI_37684"},{"id":"A55","pred":"chebi_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/CHEBI_16646"},{"id":"A54","pred":"chebi_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A52","pred":"chebi_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/CHEBI_137080"},{"id":"A50","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_16646"},{"id":"A51","pred":"chebi_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A56","pred":"chebi_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/CHEBI_18154"},{"id":"A58","pred":"chebi_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/CHEBI_16646"},{"id":"A47","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T21","span":{"begin":548,"end":556},"obj":"Species"}],"attributes":[{"id":"A21","pred":"ncbi_taxonomy_id","subj":"T21","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T44","span":{"begin":0,"end":121},"obj":"Sentence"},{"id":"T45","span":{"begin":122,"end":128},"obj":"Sentence"},{"id":"T46","span":{"begin":129,"end":252},"obj":"Sentence"},{"id":"T47","span":{"begin":253,"end":461},"obj":"Sentence"},{"id":"T48","span":{"begin":462,"end":613},"obj":"Sentence"},{"id":"T49","span":{"begin":614,"end":715},"obj":"Sentence"},{"id":"T50","span":{"begin":716,"end":848},"obj":"Sentence"},{"id":"T51","span":{"begin":849,"end":969},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"212","span":{"begin":48,"end":53},"obj":"Gene"},{"id":"217","span":{"begin":75,"end":81},"obj":"Chemical"},{"id":"218","span":{"begin":134,"end":141},"obj":"Chemical"},{"id":"219","span":{"begin":167,"end":174},"obj":"Chemical"},{"id":"220","span":{"begin":186,"end":187},"obj":"Chemical"},{"id":"221","span":{"begin":318,"end":331},"obj":"Chemical"},{"id":"213","span":{"begin":361,"end":366},"obj":"Gene"},{"id":"222","span":{"begin":439,"end":444},"obj":"Chemical"},{"id":"223","span":{"begin":470,"end":489},"obj":"Chemical"},{"id":"228","span":{"begin":548,"end":556},"obj":"Disease"},{"id":"214","span":{"begin":574,"end":605},"obj":"Gene"},{"id":"215","span":{"begin":607,"end":611},"obj":"Gene"},{"id":"216","span":{"begin":627,"end":632},"obj":"Gene"},{"id":"224","span":{"begin":633,"end":645},"obj":"Chemical"},{"id":"229","span":{"begin":725,"end":737},"obj":"Disease"},{"id":"230","span":{"begin":754,"end":767},"obj":"Disease"},{"id":"225","span":{"begin":784,"end":799},"obj":"Chemical"},{"id":"231","span":{"begin":803,"end":833},"obj":"Disease"},{"id":"226","span":{"begin":877,"end":891},"obj":"Chemical"},{"id":"227","span":{"begin":932,"end":944},"obj":"Chemical"}],"attributes":[{"id":"A218","pred":"pubann:denotes","subj":"218","obj":"MESH:D008358"},{"id":"A220","pred":"pubann:denotes","subj":"220","obj":"MESH:D009584"},{"id":"A228","pred":"pubann:denotes","subj":"228","obj":"MESH:C000657245"},{"id":"A213","pred":"pubann:denotes","subj":"213","obj":"Gene:43740568"},{"id":"A230","pred":"pubann:denotes","subj":"230","obj":"MESH:D008589"},{"id":"A212","pred":"pubann:denotes","subj":"212","obj":"Gene:43740568"},{"id":"A216","pred":"pubann:denotes","subj":"216","obj":"Gene:43740568"},{"id":"A214","pred":"pubann:denotes","subj":"214","obj":"Gene:59272"},{"id":"A224","pred":"pubann:denotes","subj":"224","obj":"MESH:D002241"},{"id":"A217","pred":"pubann:denotes","subj":"217","obj":"MESH:D011134"},{"id":"A226","pred":"pubann:denotes","subj":"226","obj":"MESH:D011134"},{"id":"A229","pred":"pubann:denotes","subj":"229","obj":"MESH:D011008"},{"id":"A225","pred":"pubann:denotes","subj":"225","obj":"MESH:D011134"},{"id":"A215","pred":"pubann:denotes","subj":"215","obj":"Gene:59272"},{"id":"A221","pred":"pubann:denotes","subj":"221","obj":"MESH:D002241"},{"id":"A219","pred":"pubann:denotes","subj":"219","obj":"MESH:D011134"},{"id":"A227","pred":"pubann:denotes","subj":"227","obj":"MESH:D002241"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T71","span":{"begin":48,"end":61},"obj":"Protein"},{"id":"T72","span":{"begin":361,"end":374},"obj":"Protein"},{"id":"T73","span":{"begin":574,"end":605},"obj":"Protein"},{"id":"T88","span":{"begin":607,"end":611},"obj":"Protein"}],"attributes":[{"id":"A71","pred":"uniprot_id","subj":"T71","obj":"https://www.uniprot.org/uniprot/P31340"},{"id":"A72","pred":"uniprot_id","subj":"T72","obj":"https://www.uniprot.org/uniprot/P31340"},{"id":"A73","pred":"uniprot_id","subj":"T73","obj":"https://www.uniprot.org/uniprot/Q9UFZ6"},{"id":"A74","pred":"uniprot_id","subj":"T73","obj":"https://www.uniprot.org/uniprot/Q9NRA7"},{"id":"A75","pred":"uniprot_id","subj":"T73","obj":"https://www.uniprot.org/uniprot/Q9BYF1"},{"id":"A76","pred":"uniprot_id","subj":"T73","obj":"https://www.uniprot.org/uniprot/Q99N71"},{"id":"A77","pred":"uniprot_id","subj":"T73","obj":"https://www.uniprot.org/uniprot/Q99N70"},{"id":"A78","pred":"uniprot_id","subj":"T73","obj":"https://www.uniprot.org/uniprot/Q8R0I0"},{"id":"A79","pred":"uniprot_id","subj":"T73","obj":"https://www.uniprot.org/uniprot/Q86WT0"},{"id":"A80","pred":"uniprot_id","subj":"T73","obj":"https://www.uniprot.org/uniprot/Q6UWP0"},{"id":"A81","pred":"uniprot_id","subj":"T73","obj":"https://www.uniprot.org/uniprot/Q5RFN1"},{"id":"A82","pred":"uniprot_id","subj":"T73","obj":"https://www.uniprot.org/uniprot/Q5EGZ1"},{"id":"A83","pred":"uniprot_id","subj":"T73","obj":"https://www.uniprot.org/uniprot/Q58DD0"},{"id":"A84","pred":"uniprot_id","subj":"T73","obj":"https://www.uniprot.org/uniprot/Q56NL1"},{"id":"A85","pred":"uniprot_id","subj":"T73","obj":"https://www.uniprot.org/uniprot/Q56H28"},{"id":"A86","pred":"uniprot_id","subj":"T73","obj":"https://www.uniprot.org/uniprot/Q2PGE2"},{"id":"A87","pred":"uniprot_id","subj":"T73","obj":"https://www.uniprot.org/uniprot/C7ECU1"},{"id":"A88","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q9UFZ6"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T84","span":{"begin":54,"end":61},"obj":"Body_part"},{"id":"T85","span":{"begin":134,"end":141},"obj":"Body_part"},{"id":"T86","span":{"begin":318,"end":331},"obj":"Body_part"},{"id":"T87","span":{"begin":367,"end":374},"obj":"Body_part"},{"id":"T88","span":{"begin":477,"end":489},"obj":"Body_part"},{"id":"T89","span":{"begin":633,"end":645},"obj":"Body_part"},{"id":"T90","span":{"begin":784,"end":799},"obj":"Body_part"},{"id":"T91","span":{"begin":877,"end":891},"obj":"Body_part"},{"id":"T92","span":{"begin":932,"end":944},"obj":"Body_part"}],"attributes":[{"id":"A92","pred":"fma_id","subj":"T92","obj":"http://purl.org/sig/ont/fma/fma82737"},{"id":"A84","pred":"fma_id","subj":"T84","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A85","pred":"fma_id","subj":"T85","obj":"http://purl.org/sig/ont/fma/fma82801"},{"id":"A89","pred":"fma_id","subj":"T89","obj":"http://purl.org/sig/ont/fma/fma82737"},{"id":"A90","pred":"fma_id","subj":"T90","obj":"http://purl.org/sig/ont/fma/fma82746"},{"id":"A86","pred":"fma_id","subj":"T86","obj":"http://purl.org/sig/ont/fma/fma82737"},{"id":"A88","pred":"fma_id","subj":"T88","obj":"http://purl.org/sig/ont/fma/fma82737"},{"id":"A87","pred":"fma_id","subj":"T87","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A91","pred":"fma_id","subj":"T91","obj":"http://purl.org/sig/ont/fma/fma82746"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T5","span":{"begin":188,"end":201},"obj":"http://purl.obolibrary.org/obo/GO_0070085"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T21","span":{"begin":548,"end":556},"obj":"Disease"}],"attributes":[{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T6","span":{"begin":188,"end":201},"obj":"http://purl.obolibrary.org/obo/GO_0070085"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T6","span":{"begin":186,"end":201},"obj":"http://purl.obolibrary.org/obo/GO_0006487"},{"id":"T7","span":{"begin":188,"end":201},"obj":"http://purl.obolibrary.org/obo/GO_0070085"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}

{"project":"LitCovid-sentences","denotations":[{"id":"T44","span":{"begin":0,"end":121},"obj":"Sentence"},{"id":"T45","span":{"begin":122,"end":128},"obj":"Sentence"},{"id":"T46","span":{"begin":129,"end":252},"obj":"Sentence"},{"id":"T47","span":{"begin":253,"end":461},"obj":"Sentence"},{"id":"T48","span":{"begin":462,"end":613},"obj":"Sentence"},{"id":"T49","span":{"begin":614,"end":715},"obj":"Sentence"},{"id":"T50","span":{"begin":716,"end":848},"obj":"Sentence"},{"id":"T51","span":{"begin":849,"end":969},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}

{"project":"LitCovid-sample-Glycan","denotations":[{"id":"T2","span":{"begin":134,"end":141},"obj":"http://rdf.glyconavi.org/CarTNa/CarTNa218/trivialname"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}

{"project":"LitCovid-PubTator","denotations":[{"id":"212","span":{"begin":48,"end":53},"obj":"Gene"},{"id":"213","span":{"begin":361,"end":366},"obj":"Gene"},{"id":"214","span":{"begin":574,"end":605},"obj":"Gene"},{"id":"215","span":{"begin":607,"end":611},"obj":"Gene"},{"id":"216","span":{"begin":627,"end":632},"obj":"Gene"},{"id":"217","span":{"begin":75,"end":81},"obj":"Chemical"},{"id":"218","span":{"begin":134,"end":141},"obj":"Chemical"},{"id":"219","span":{"begin":167,"end":174},"obj":"Chemical"},{"id":"220","span":{"begin":186,"end":187},"obj":"Chemical"},{"id":"221","span":{"begin":318,"end":331},"obj":"Chemical"},{"id":"222","span":{"begin":439,"end":444},"obj":"Chemical"},{"id":"223","span":{"begin":470,"end":489},"obj":"Chemical"},{"id":"224","span":{"begin":633,"end":645},"obj":"Chemical"},{"id":"225","span":{"begin":784,"end":799},"obj":"Chemical"},{"id":"226","span":{"begin":877,"end":891},"obj":"Chemical"},{"id":"227","span":{"begin":932,"end":944},"obj":"Chemical"},{"id":"228","span":{"begin":548,"end":556},"obj":"Disease"},{"id":"229","span":{"begin":725,"end":737},"obj":"Disease"},{"id":"230","span":{"begin":754,"end":767},"obj":"Disease"},{"id":"231","span":{"begin":803,"end":833},"obj":"Disease"}],"attributes":[{"id":"A212","pred":"tao:has_database_id","subj":"212","obj":"Gene:43740568"},{"id":"A213","pred":"tao:has_database_id","subj":"213","obj":"Gene:43740568"},{"id":"A214","pred":"tao:has_database_id","subj":"214","obj":"Gene:59272"},{"id":"A215","pred":"tao:has_database_id","subj":"215","obj":"Gene:59272"},{"id":"A216","pred":"tao:has_database_id","subj":"216","obj":"Gene:43740568"},{"id":"A217","pred":"tao:has_database_id","subj":"217","obj":"MESH:D011134"},{"id":"A218","pred":"tao:has_database_id","subj":"218","obj":"MESH:D008358"},{"id":"A219","pred":"tao:has_database_id","subj":"219","obj":"MESH:D011134"},{"id":"A220","pred":"tao:has_database_id","subj":"220","obj":"MESH:D009584"},{"id":"A221","pred":"tao:has_database_id","subj":"221","obj":"MESH:D002241"},{"id":"A224","pred":"tao:has_database_id","subj":"224","obj":"MESH:D002241"},{"id":"A225","pred":"tao:has_database_id","subj":"225","obj":"MESH:D011134"},{"id":"A226","pred":"tao:has_database_id","subj":"226","obj":"MESH:D011134"},{"id":"A227","pred":"tao:has_database_id","subj":"227","obj":"MESH:D002241"},{"id":"A228","pred":"tao:has_database_id","subj":"228","obj":"MESH:C000657245"},{"id":"A229","pred":"tao:has_database_id","subj":"229","obj":"MESH:D011008"},{"id":"A230","pred":"tao:has_database_id","subj":"230","obj":"MESH:D008589"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In the so‐called receptor‐binding domain of the spike protein there are 22 glycan‐binding sites (Shahajan, Supekar et al. 2020). High mannose, hybrid and complex‐type glycans across the N‐glycosylation sites have been identified with mass spectrometry. One could imagine building a therapeutic which might contain the carbohydrates, or a suitable mimic, of the spike protein coupled to a carrier molecule, much in a similar fashion to how PPSGG was constructed. Such a “decoy” carbohydrate could block the binding and subsequent internalization of COViD‐19 to its receptor, angiotensin converting enzyme‐2 (ACE2). In addition, spike carbohydrate clusters coupled to a carrier might proof to be an effective vaccine. Both the pneumococcal vaccine and the meningococcal vaccines target polysaccharides in pneumococcus and meningococcus, respectively. They couple the appropriate polysaccharide to a suitable carrier to achieve potent carbohydrate‐specific immunogenicity."}